PF-06863135
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PF-06863135, covering 2025-03-18 to 2025-03-18. Get the full timeline:
Most recent: Clinical Trial Update: PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma [Phase 1]